Nucleic Acid Vaccines

Self-Replicating RNA Vaccine for Cancer, Disease Therapy

Published in Vaccine Weekly, August 23rd, 1999

A self-replicating RNA vaccine not only protected mice against tumor challenge but also improved survival in mice with established tumors.

The vaccine "self replicates" by borrowing a replicase polyprotein derived from Semliki forest virus. The replicase (Rep-LacZ) drives replication of the RNA to which it is linked. This greatly increases the amount of vaccine-encoding RNA within the target cell.

The vaccine's extraordinary efficacy, however, is not a direct result of extra antigen: in vitro studies showed that it produced only a little more than twice as much antigen as a conventional DNA vaccine. Instead, the self-replicating vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-08-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry